Summary
Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, and for which effective treatments are lacking. The European V.A. Cure network aims to address this unmet medical need by uncovering core mechanisms of disease initiation and maintenance and by leveraging this information for establishing novel therapeutic strategies for VAs.
V.A. Cure has assembled 7 world-leading academic laboratories and 5 companies, which will apply an intersectoral four-step approach: (1) identification of novel genes involved in VAs in patients, (2) dissection of molecular mechanisms behind the diseases by in vitro modelling, (3) in-depth analysis of tissular mechanisms in pathophysiological conditions through in vivo models, and (4) pre-clinical testing of identified treatment strategies. The knowledge gained will not only be relevant for VAs but also for understanding aberrant vascular function in other vascular-related diseases.
The composition of V.A. Cure and close interaction between the 14 ESRs, through secondments in academia and industry, guarantee a unique intersectoral training program at the highest level, ensuring a comprehensive perception of research and drug/technology development in pharma industry/biotech and academia. ESRs will be trained in a plethora of cutting-edge technologies including next-generation sequencing (up to single-cell RNA-Seq), CRISPR-Cas genome editing, generation of animal models with inducible deletion and mosaic analyses, generation of iPSCs, microfluidics, in vivo phage display to identify endothelial targets, and light sheet-, confocal-, and multiphoton live-imaging. In combination with advanced training in management and communication including writing, presentation, e-media and outreach, the graduates of the V.A. Cure network will be future leaders in vascular research, and also highly competitive candidates for positions outside academia.
V.A. Cure has assembled 7 world-leading academic laboratories and 5 companies, which will apply an intersectoral four-step approach: (1) identification of novel genes involved in VAs in patients, (2) dissection of molecular mechanisms behind the diseases by in vitro modelling, (3) in-depth analysis of tissular mechanisms in pathophysiological conditions through in vivo models, and (4) pre-clinical testing of identified treatment strategies. The knowledge gained will not only be relevant for VAs but also for understanding aberrant vascular function in other vascular-related diseases.
The composition of V.A. Cure and close interaction between the 14 ESRs, through secondments in academia and industry, guarantee a unique intersectoral training program at the highest level, ensuring a comprehensive perception of research and drug/technology development in pharma industry/biotech and academia. ESRs will be trained in a plethora of cutting-edge technologies including next-generation sequencing (up to single-cell RNA-Seq), CRISPR-Cas genome editing, generation of animal models with inducible deletion and mosaic analyses, generation of iPSCs, microfluidics, in vivo phage display to identify endothelial targets, and light sheet-, confocal-, and multiphoton live-imaging. In combination with advanced training in management and communication including writing, presentation, e-media and outreach, the graduates of the V.A. Cure network will be future leaders in vascular research, and also highly competitive candidates for positions outside academia.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/814316 |
| Start date: | 01-03-2019 |
| End date: | 28-02-2023 |
| Total budget - Public funding: | 3 792 135,60 Euro - 3 792 135,00 Euro |
Cordis data
Original description
Vascular anomalies (VAs) is a group of rare diseases defined by blood- or lymph vessel dysfunction causing chronic pain, disabilities, and even sudden death, and for which effective treatments are lacking. The European V.A. Cure network aims to address this unmet medical need by uncovering core mechanisms of disease initiation and maintenance and by leveraging this information for establishing novel therapeutic strategies for VAs.V.A. Cure has assembled 7 world-leading academic laboratories and 5 companies, which will apply an intersectoral four-step approach: (1) identification of novel genes involved in VAs in patients, (2) dissection of molecular mechanisms behind the diseases by in vitro modelling, (3) in-depth analysis of tissular mechanisms in pathophysiological conditions through in vivo models, and (4) pre-clinical testing of identified treatment strategies. The knowledge gained will not only be relevant for VAs but also for understanding aberrant vascular function in other vascular-related diseases.
The composition of V.A. Cure and close interaction between the 14 ESRs, through secondments in academia and industry, guarantee a unique intersectoral training program at the highest level, ensuring a comprehensive perception of research and drug/technology development in pharma industry/biotech and academia. ESRs will be trained in a plethora of cutting-edge technologies including next-generation sequencing (up to single-cell RNA-Seq), CRISPR-Cas genome editing, generation of animal models with inducible deletion and mosaic analyses, generation of iPSCs, microfluidics, in vivo phage display to identify endothelial targets, and light sheet-, confocal-, and multiphoton live-imaging. In combination with advanced training in management and communication including writing, presentation, e-media and outreach, the graduates of the V.A. Cure network will be future leaders in vascular research, and also highly competitive candidates for positions outside academia.
Status
CLOSEDCall topic
MSCA-ITN-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| DE DUVE INSTITUTE AISBL (Coördinator)
-
| ASTRAZENECA AB
-
| BAYER AKTIENGESELLSCHAFT (BAYER)
-
| BELGIAN VASCULAR ANOMALY PATIENT ASSOCIATION
-
| CLINIQUE UNIVERSITAIRE SAINT-LUC ASBL
-
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
-
| KAROLINSKA INSTITUTET
-
| LLS ROWIAK LASERLABSOLUTIONS GMBH
-
| MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
-
| NAVINCI DIAGNOSTICS AB
-
| Perimed AB
-
| SINGH PRATEEK
-
| Sysmex Inostics GmbH
-
| TAMPEREEN KORKEAKOULUSAATIO SR
-
| UNIVERSITAET POTSDAM